GC Therapeutics utilizes a "plug-and-play" induced pluripotent stem cell (iPSC) programming platform, TFome™, to efficiently generate various cell types for cell therapies. This technology addresses the challenges of scalability and accessibility in cell therapy development, enabling the rapid production of off-the-shelf iPSC-based medicines for gastrointestinal, neurological, and immunological diseases.
Funding
$74.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CAFounders
Product
Problem
Producing cell therapies at scale is challenging due to the complexities of cell programming and manufacturing. Traditional methods for generating induced pluripotent stem cell (iPSC)-based medicines are often slow, inefficient, and costly, limiting patient access.
Solution
GC Therapeutics (GCTx) offers a "plug-and-play" iPSC programming platform called TFome™ (Transcription-Factor-ome) designed to streamline cell therapy development. TFome™ leverages synthetic biology, gene editing, cell engineering, and machine learning to rapidly generate various cell types for therapeutic applications. The platform aims to overcome scalability challenges by enabling the efficient production of off-the-shelf iPSC-based medicines with improved potency, efficiency, quality, and cost compared to conventional methods. GCTx is advancing a pipeline of cell therapy programs focused on gastrointestinal, neurological, and immunological diseases.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions involved in cell therapy development, particularly those focused on gastrointestinal, neurological, and immunological diseases.
Features
- TFome™ platform for rapid, single-step iPSC programming
- Utilizes synthetic biology, gene editing, cell engineering, and machine learning
- Aims for 100x faster cell production compared to traditional methods
- Improved cell potency, efficiency, and quality
- Scalable manufacturing process for off-the-shelf cell therapies